Daraxonrasib (RMC-6236) - An investigational, oral, multi-selective RAS(ON) inhibitor designed by Revolution Medicines to treat cancers with KRAS mutations​ - RASolute 302 trial (NCT06625320) is a pivotal Phase 3 global study evaluating daraxonrasib (RMC-6236) as a monotherapy for previously treatedmetastatic pancreatic ductal adenocarcinoma (PDAC)​.​